Status:
COMPLETED
Minocycline in Patients With Alzheimer's Disease
Lead Sponsor:
Huntington Medical Research Institutes
Conditions:
Mild Cognitive Impairment
Alzheimer's Disease
Eligibility:
All Genders
55-90 years
Phase:
PHASE2
Brief Summary
Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitat...
Detailed Description
In the course of on-going trials of novel MRI procedures for Neurological Diagnosis, the investigators have established non-invasive BIOMARKERS (Note: Biomarkers are objective Laboratory tests used in...
Eligibility Criteria
Inclusion
- Cognitively normal elderly subjects between the ages of 55-90 and patients aged 55 - 90 years who have mild cognitive impairment (MCI) or clinically defined Alzheimer's disease.
Exclusion
- Any person with medical devices such as cardiac pacemakers/defibrillators or neuro-implants as they are contra-indications for MRI/MRS exam.
- Since the effects of MRI are unknown to the fetus or unborn child, any person who is or may be pregnant will be excluded from the study.
- History of known allergy or intolerance to minocycline or any other tetracycline
- Impaired renal function (plasma Creatinine) or blood urea nitrogen (BUN) levels exceeds twice normal upper limit which can result in higher serum levels of tetracycline, azotemia, hyperphosphatemia and acidosis.
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT01463384
Start Date
September 1 2011
End Date
October 1 2012
Last Update
September 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Huntington Medical Research Institutes
Pasadena, California, United States, 91105